TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11220420

Group type: EXPERIMENTAL
Intervention: Rocuronium for intubation and maintenance (Group RR)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Pancuronium for intubation and rocuronium for maintenance (Group PR)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Pancuronium for both intubation and maintenance (Group PP)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Rocuronium for intubation followed by pancuronium for maintenance (Group RP)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Pancuronium for both doses (Group PP)
Number of subjects: 78
Study: 9433370

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 60 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 120 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 7950181

Group type: EXPERIMENTAL
Intervention: No. 90 Dasheng Jiangya (DSJY) oral liquid
Number of subjects: 109

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 109
Study: 3307992

Group type: EXPERIMENTAL
Intervention: Interrupted closure with polyglactin
Number of subjects: 1491

Group type: EXPERIMENTAL
Intervention: Continuous closure with polyglactin
Number of subjects: 1491

Group type: EXPERIMENTAL
Intervention: Continuous closure with polydioxanone
Number of subjects: 1491

Group type: EXPERIMENTAL
Intervention: Continuous closure with nylon
Number of subjects: 1491

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1491
Study: 29879469

Group type: EXPERIMENTAL
Intervention: HoPS+ (Homens para Saúde Mais) intervention
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1080
Study: 27065308

Group type: EXPERIMENTAL
Intervention: Nutrition education (NEd) using Health Belief Model (HBM), provided twice monthly for 6 months to the intervention group (n = 80)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual education for control mothers
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Nutrition education (NEd) using Health Belief Model (HBM)
Number of subjects: 160
Study: 25057076

Group type: EXPERIMENTAL
Intervention: Modified right ventricular outflow tract pacing (MRVOTP)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Conventional right ventricular outflow tract pacing (CRVOTP)
Number of subjects: 136
Study: 22961605

Group type: EXPERIMENTAL
Intervention: Acupuncture (AC) administered in 20 sessions over 10 weeks
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Tanacetum (TAN) at 150 mg/day
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Combined treatment (AC+TAN)
Number of subjects: 69
Study: 20400483

Group type: EXPERIMENTAL
Intervention: Provider initiated primary care outreach intervention
Number of subjects: 719

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 719
Study: 19011431

Group type: EXPERIMENTAL
Intervention: CP-101,606
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16167916

Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride (60 mg/day) plus calcium (500 mg/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Calcium (500 mg/day)
Number of subjects: 39
Study: 12763376

Group type: EXPERIMENTAL
Intervention: Lamivudine (100 mg) for 52 weeks
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Lamivudine plus interferon for 24 weeks
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study: 10690862

Group type: EXPERIMENTAL
Intervention: 20K-hGH
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8843176

Group type: EXPERIMENTAL
Intervention: Urapidil 60 mg twice per day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Atenolol 50 mg once per day
Number of subjects: 42
Study: 1321894

Group type: EXPERIMENTAL
Intervention: Half-dose chemotherapy (50% dose reduction of all chemotherapeutic agents)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Full-dose chemotherapy (in older children)
Number of subjects: 256
Study: 6360295

Group type: EXPERIMENTAL
Intervention: Mazindol
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30626611

Group type: EXPERIMENTAL
Intervention: GIP(3‐30)NH2 plus exendin(9‐39)NH2
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GIP(3‐30)NH2
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: exendin(9‐39)NH2
Number of subjects: 18

Group type: COMPARATOR
Intervention: saline
Number of subjects: 18
Study: 30335579

Group type: EXPERIMENTAL
Intervention: Hot water immersion (HWI) at 39°C for 1 hour
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 hot water immersion sessions (INT) over 2 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 10
Study: 27778457

Group type: EXPERIMENTAL
Intervention: Digital 12-lead Holter ECG
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard ECG
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Holter ECG
Number of subjects: 34
Study: 24810491

Group type: EXPERIMENTAL
Intervention: Early ART (starting after 2 weeks of tuberculosis treatment)
Number of subjects: 1675

Group type: COMPARATOR
Intervention: Delayed ART (placebo, then starting ART at the end of 6 months of tuberculosis treatment)
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Early ART (CD4 count 220-349 cells per μL)
Number of subjects: 1675

Group type: COMPARATOR
Intervention: Delayed ART (CD4 count 220-349 cells per μL)
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Early ART (CD4 count 350 cells per μL or more)
Number of subjects: 1675

Group type: COMPARATOR
Intervention: Delayed ART (CD4 count 350 cells per μL or more)
Number of subjects: 1675

Group type: EXPERIMENTAL
Intervention: Early ART
Number of subjects: 1675
Study: 21822762

Group type: EXPERIMENTAL
Intervention: Parent training (PT) added to antipsychotic medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication plus PT
Number of subjects: 0
Study: 19200788

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corticosteroids (dexamethasone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 17972062

Group type: EXPERIMENTAL
Intervention: Minimally invasive total knee arthroplasty with computer-assisted navigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty
Number of subjects: 0
Study: 15108570

Group type: EXPERIMENTAL
Intervention: Telephone intervention consisting of six calls over eight weeks discussing safety-promoting behaviors.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (Control group).
Number of subjects: 150
Study: 11803730

Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg/day
Number of subjects: 1061

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 1061

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/day
Number of subjects: 1061

Group type: EXPERIMENTAL
Intervention: Naproxen 1000 mg/day
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061
Study: 9667265

Group type: EXPERIMENTAL
Intervention: Thoracic radiation therapy starting on day 1 of chemotherapy (arm I)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Thoracic radiation therapy starting on day 64 of chemotherapy (arm II)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Chemotherapy alone (arm III)
Number of subjects: 399
Study: 7830803

Group type: EXPERIMENTAL
Intervention: New biscuit (25 biscuits of 15.5 g each in 2 weeks)
Number of subjects: 10
Study: 2974715

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg day‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5 mg day‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combination of cilazapril and propranolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Combined therapy of cilazapril and propranolol
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29490031

Group type: EXPERIMENTAL
Intervention: Metformin 1700 or 2000 mg/d
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 27655517

Group type: EXPERIMENTAL
Intervention: Professional oral health care (POHC) and Mucosamin® during recovery after transplantation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Clorexidine 0.20% (control)
Number of subjects: 68
Study: 24491034

Group type: EXPERIMENTAL
Intervention: Positive Outlook online self-management program (90 minutes per week for 7 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 0
Study: 22794117

Group type: EXPERIMENTAL
Intervention: Eldecalcitol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alfacalcidol
Number of subjects: 0
Study: 20829713

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (O) 10 mg once-daily, with possible dose increase to 40 mg
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Ramipril (R) 2.5 mg once-daily, with possible dose increase to 10 mg
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil (O)
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Ramipril (R)
Number of subjects: 1102
Study: 18533736

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination therapy with statins (e.g., niacin/lovastatin, ezetimibe/simvastatin, amlodipine/atorvastatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin/pravastatin
Number of subjects: 0
Study: 15919088

Group type: EXPERIMENTAL
Intervention: 1000 microg of rectal misoprostol administered by traditional birth attendants (TBAs) in the intervention area.
Number of subjects: 849

Group type: COMPARATOR
Intervention: Non-intervention group (no misoprostol treatment, referred to nearest facility).
Number of subjects: 849
Study: 14655926

Group type: EXPERIMENTAL
Intervention: 2.5-mg slow-release melatonin
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: 10-mg melatonin
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 11018193

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg once daily
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 9011975

Group type: EXPERIMENTAL
Intervention: Finasteride (5 mg daily)
Number of subjects: 707

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 707
Study: 1639636

Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI) at 12 Gy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI) at 14 Gy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI) at 16 Gy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI) at 17 Gy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Overall survival post-transplant
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Relapse rate post-transplant
Number of subjects: 36
Study: 6144462

Group type: COMPARATOR
Intervention: Lorazepam 0.5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lorazepam 1.0 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lorazepam 2.0 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diazepam 5.0 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lorazepam (various doses)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 12
Study: 28810425

Group type: EXPERIMENTAL
Intervention: Weight-focused campaigns
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weight-neutral campaigns
Number of subjects: 0
Study: 30276500

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 1622

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 1622

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1622

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg (CM)
Number of subjects: 1622

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg (CM)
Number of subjects: 1622
Study: 26271677

Group type: EXPERIMENTAL
Intervention: 2.0 adult-METs
Number of subjects: 102

Group type: COMPARATOR
Intervention: 1.5 adult-METs
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 1.5 child-METs
Number of subjects: 102
Study: 24795503

Group type: EXPERIMENTAL
Intervention: Probiotic (VSL#3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both omega-3 and probiotic (VSL#3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 22474401

Group type: EXPERIMENTAL
Intervention: Nifedipine-telmisartan combination treatment
Number of subjects: 0
Study: 21313903

Group type: EXPERIMENTAL
Intervention: pethidine + ketamine (5 mg pethidine and 0.25 mg kg(‐1) ketamine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: pethidine + placebo (10 mg pethidine and NS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: pethidine + ketamine
Number of subjects: 100

Group type: COMPARATOR
Intervention: pethidine + placebo
Number of subjects: 100
Study: 18037745

Group type: EXPERIMENTAL
Intervention: Transthoracic Doppler echocardiography with intravenous administration of adenosine (0.16 mg.kg(‐1).min(‐1))
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Transthoracic Doppler echocardiography
Number of subjects: 32
Study: 16229850

Group type: EXPERIMENTAL
Intervention: Y402H polymorphism
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Baseline plasma C-reactive protein levels
Number of subjects: 685
Study: 12823878

Group type: EXPERIMENTAL
Intervention: Wearing a cervical orthosis (neck brace) during the first drive (Group A)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Not wearing a cervical orthosis during the first drive (Group B)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Wearing a cervical orthosis (neck brace) during the second drive (Group B)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Not wearing a cervical orthosis during the second drive (Group A)
Number of subjects: 23
Study: 11111290

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO) in addition to relief of weightbearing structures (Gr. II)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Relief of weightbearing structures only (Gr. I)
Number of subjects: 20
Study: 8868017

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular magnesium sulfate regimen
Number of subjects: 0
Study: 1299709

Group type: EXPERIMENTAL
Intervention: Regimen A, standard dosage of clofazimine (CLO) in multidrug therapy (MDT) regimen
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Regimen B, CLO 600 mg once every 4 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Regimen C, CLO 1200 mg once every 4 weeks
Number of subjects: 45
Study: 6608419

Group type: EXPERIMENTAL
Intervention: Potassium cardioplegic solutions with added blood (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Crystalloid potassium cardioplegics (group C)
Number of subjects: 60
Study: 31951305

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval exercise
Number of subjects: 0
Study: 30628813

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg for five days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (for five days)
Number of subjects: 31
Study: 27794196

Group type: EXPERIMENTAL
Intervention: One apple (low consumption)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Two apples (medium consumption)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Four apples (high consumption)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (abstaining from apples)
Number of subjects: 30
Study: 26391511

Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy with weekly mobile phone messages for three months
Number of subjects: 144

Group type: COMPARATOR
Intervention: Post-HIV test counselling
Number of subjects: 144
Study: 23393209

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 432

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 432
Study: 21529848

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 880

Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting
Number of subjects: 880
Study: 18336488

Group type: EXPERIMENTAL
Intervention: Interactive online teaching modules and simulated critical incident scenarios
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated scenario supplemented by online teaching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive drug administration teaching using an online module and high fidelity simulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Poor simulator score
Number of subjects: 0
Study: 16520042

Group type: EXPERIMENTAL
Intervention: Automode ventilation (group A, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional ventilation (group B, n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Automode ventilation (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional ventilation (group B)
Number of subjects: 20
Study: 14579065

Group type: EXPERIMENTAL
Intervention: Preventive home visits by a specially trained nurse
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Screening and assessment
Number of subjects: 77
Study: 10699339

Group type: EXPERIMENTAL
Intervention: Trivalent cold-adapted influenza vaccine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Natural immunity from influenza A infection in year 1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9200764

Group type: EXPERIMENTAL
Intervention: Levomepromazine (50 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Thioridazine (50 mg/day)
Number of subjects: 26
Study: 1405328

Group type: EXPERIMENTAL
Intervention: Flat plate (FP) dialyzer
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hollow fiber (HF) dialyzer
Number of subjects: 12

Group type: COMPARATOR
Intervention: EPO therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both dialyzer types (FP and HF)
Number of subjects: 12
Study: 3882371

Group type: EXPERIMENTAL
Intervention: New device for giving multiple injections of short‐acting insulin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional syringes for injections of short‐acting insulin
Number of subjects: 16
Study: 31258128

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0
Study: 29331343

Group type: EXPERIMENTAL
Intervention: Irradiation stent
Number of subjects: 328

Group type: COMPARATOR
Intervention: Uncovered self-expandable metallic stent (SEMS)
Number of subjects: 328
Study: 27468542

Group type: EXPERIMENTAL
Intervention: Qingxue Dan (QXD) 900 mg/d for 8 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 24509284

Group type: EXPERIMENTAL
Intervention: Hypothermia induced by rapid infusion of 600 to 2,000 ml cold saline and endovascular cooling
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 120
Study: 23057611

Group type: EXPERIMENTAL
Intervention: Pulsatile dry cupping (8 sessions within 4 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 40
Study: 21252603

Group type: EXPERIMENTAL
Intervention: Hospital-based exercise program (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Home-based exercise program (n=30)
Number of subjects: 60
Study: 17556425

Group type: EXPERIMENTAL
Intervention: 2 l fill of dialysate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3 l fill of dialysate
Number of subjects: 15
Study: 16224653

Group type: EXPERIMENTAL
Intervention: Laparoscopic operation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open operation
Number of subjects: 60
Study: 11942049

Group type: EXPERIMENTAL
Intervention: Intermittent maintenance chemotherapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 25
Study: 9467547

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg cyclic
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily and cyclic
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 111
Study: 7637185

Group type: EXPERIMENTAL
Intervention: Dopamine (DOA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 2529410

Group type: EXPERIMENTAL
Intervention: Ethanol solution (0.5 g ethanol/kg B.Wt.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 0
Study: 676644

Group type: EXPERIMENTAL
Intervention: Intravenous naloxone (0.04 mg increments every 3 min) until ET(CO2) < 8% (group I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous naloxone (0.04 mg increments every 3 min) until ET(CO2) < 6.5% (group II)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous naloxone (0.04 mg increments every 3 min) + additional intramuscular naloxone (group III)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous naloxone (0.04 mg increments every 3 min) + additional intramuscular naloxone (group IV)
Number of subjects: 60
Study: 30620614

Group type: EXPERIMENTAL
Intervention: 5 Hz NMES
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 Hz NMES
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 50 Hz NMES
Number of subjects: 16

Group type: COMPARATOR
Intervention: 10 Hz and 50 Hz NMES
Number of subjects: 16
Study: 28087725

Group type: EXPERIMENTAL
Intervention: High PCO2 target
Number of subjects: 359

Group type: COMPARATOR
Intervention: Control group with mildly elevated PCO2 targets
Number of subjects: 359
Study: 26159018

Group type: EXPERIMENTAL
Intervention: Anatomic shape bracket splints
Number of subjects: 60

Group type: COMPARATOR
Intervention: Common splints
Number of subjects: 60
Study: 24347520

Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy (STPP)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 157